Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vaxcyte, Inc. (PCVX)
NASDAQ:PCVX
Vaxcyte (PCVX) Stock Price & Analysis
177 Followers
PCVX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$44.20 - $85.61
Previous Close$81.63
Volume836.67K
Average Volume (3M)736.32K
Market Cap
$8.88B
Enterprise Value$7.42B
Total Cash (Recent Filing)$1.49B
Total Debt (Recent Filing)$27.42M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Aug 06, 2024EPS Estimate
-$0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.36
Shares Outstanding108,795,188
10 Day Avg. Volume629,084
30 Day Avg. Volume736,323
Standard Deviation0.18
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)6.57
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-15.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-15.74
Forecast
1Y Price Target
$103.00Price Target Upside26.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Vaxcyte News
PremiumCompany Announcements
Vaxcyte Appoints John Furey as New Independent Board Director
PremiumPress Releases
Vaxcyte Appoints John Furey to Board of Directors
Bulls Say, Bears Say
Bulls Say
Biopharma IndustryVaxcyte’s Ph2 data for VAX-31 pneumococcal vaccine represents a major catalyst with favorable risk/reward.
Market ImpactThe VAX-31 data will mark the first 30+ valent clinical data in the landscape with potential to disrupt Pfizer's near-monopoly on an ~$8Bn+ PCV market.
Vaccine CoverageVAX-31 is designed to offer the broadest coverage, potential for compelling cost-effectiveness relative to other vaccines, and a profile which would help ACIP simplify its vaccine schedules upon approval.
Bears Say
Conflict Of InterestInvestors should consider the potential conflict of interest as Mizuho Securities USA LLC seeks to do business with the companies covered in its research reports.
Market TrendsThe rising prevalence of Serotype 4 was another discussion point.
Product CoverageCapvaxive does not include serotype 4 coverage, which is important for certain under-represented racial/socioeconomic populations.
---
Ownership Overview
18.56% Insiders
46.09% Mutual Funds
15.52% Other Institutional Investors
19.82% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PCVX FAQ
What was Vaxcyte, Inc.’s price range in the past 12 months?
Vaxcyte, Inc. lowest stock price was $44.20 and its highest was $85.61 in the past 12 months.
What is Vaxcyte, Inc.’s market cap?
Currently, no data Available
When is Vaxcyte, Inc.’s upcoming earnings report date?
Vaxcyte, Inc.’s upcoming earnings report date is Aug 06, 2024 which is in 15 days.
How were Vaxcyte, Inc.’s earnings last quarter?
Vaxcyte, Inc. released its earnings results on May 08, 2024. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$1.129 by $0.279.
Is Vaxcyte, Inc. overvalued?
According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued.
Does Vaxcyte, Inc. pay dividends?
Vaxcyte, Inc. does not currently pay dividends.
What is Vaxcyte, Inc.’s EPS estimate?
Vaxcyte, Inc.’s EPS estimate is -$0.98.
How many shares outstanding does Vaxcyte, Inc. have?
Vaxcyte, Inc. has 108,795,190 shares outstanding.
What happened to Vaxcyte, Inc.’s price movement after its last earnings report?
Vaxcyte, Inc. reported an EPS of -$0.85 in its last earnings report, beating expectations of -$1.129. Following the earnings report the stock price went down -1.827%.
Which hedge fund is a major shareholder of Vaxcyte, Inc.?
Among the largest hedge funds holding Vaxcyte, Inc.’s share is RA Capital Management. It holds Vaxcyte, Inc.’s shares valued at 560M.
---
Vaxcyte Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$103.00 (26.18% Upside)
$103.00 (26.18% Upside)
Blogger Sentiment
Bullish
PCVX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.54%
12-Months-Change
Fundamentals
Return on Equity
-29.83%
Trailing 12-Months
Asset Growth
107.44%
Trailing 12-Months
Company Description
Vaxcyte, Inc.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from most common and deadly diseases.
---
PCVX Company Deck
---
PCVX Earnings Call
Q4 2024
0:00 / 0:00
---
PCVX Stock 12 Month Forecast
Average Price Target
$103.00
▲(26.18% Upside)
Technical Analysis
Best Analysts Covering PCVX
1 Year
1 Year Success Rate
12/12 ratings generated profit
1 Year Average Return
+44.67%
reiterated a buy rating 25 days ago
Copying David Risinger's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +44.67% per trade.
---